Glory Health Industry Limited 2025 Annual Report: Critical Updates for Investors

Executive Summary

Glory Health Industry Limited (“the Group”, formerly known as Glory Land Company Limited) has released its annual report for the year ended December 31, 2025. The report contains several crucial updates and disclosures that are highly relevant for investors, highlighting ongoing market challenges, a significant net loss, liquidity concerns, and changes in the company’s strategic direction.

Key Financial Highlights

• Total Revenue: RMB 1,035.6 million in 2025, down significantly from RMB 2,705.3 million in 2024.
• Revenue from Property Development: RMB 606.6 million.
• Net Loss: RMB 1,769.4 million for 2025, compared to a loss of RMB 1,415.5 million in 2024.
• Loss Attributable to Owners: RMB 1,822.5 million, with basic and diluted loss per share at RMB 0.41.
• No Final Dividend: The Board did not recommend any final dividend for 2025.
• Cash and Cash Equivalents: RMB 47.1 million as of December 31, 2025.
• Bank and Other Borrowings Due Within One Year: RMB 7,569.1 million, highlighting major short-term liquidity pressure.
• Total Investment Properties: RMB 20.14 billion.
• Distributable Reserves: RMB 1,634.1 million.

Critical Issues Highlighted

• Going Concern Uncertainties:
  • The independent auditors have issued a Disclaimer of Opinion on the consolidated financial statements due to significant uncertainties regarding the Group’s ability to continue as a going concern.
  • Failure to meet scheduled repayments on senior notes (RMB 3,700.4 million) and bank and other borrowings (RMB 5,766.3 million) could lead to demands for immediate repayment and possible default.
  • Management’s mitigation measures include negotiating debt extensions, selling investment properties, boosting property sales, and cost control. However, these plans are subject to uncertainty and their success is not guaranteed.
• Liquidity Risk:
  • The company relies heavily on proceeds from pre-sale of properties to finance its development and construction activities. Market sentiment and sales performance are critical to liquidity.
  • Should the Group fail to refinance, sell assets, or achieve targeted sales, it may not be able to meet its obligations, which may result in significant asset write-downs and reclassification of assets and liabilities.
• Market and Regulatory Environment:
  • 2025 saw a shift in government policies from demand-side stimulus to supply-side reforms, which has not yet fully stabilized the industry.
  • The sector remains in a “survival of the fittest” state, with high competition and the risk of further market consolidation or exits by weaker players.
• Strategic Direction:
  • The Group is planning to diversify into the health industry and explore new markets beyond real estate, although concrete details and financial impacts are not yet disclosed.
• Auditor Rotation:
  • WM CPA Limited was appointed in January 2025, succeeding Solar CPA Limited. WM CPA Limited has issued a disclaimer of opinion for the 2025 accounts.
• Shareholding and Governance:
  • Chairman Zhang Zhangsun, through Alltogether, controls 76.71% of the Company’s shares. Ms. Ruan Wenjuan (executive director and spouse of Chairman Zhang) is deemed interested in the same stake.
  • No director or substantial shareholder is reported to have breached non-competition undertakings.
  • The Company continues to maintain the minimum required public float under its waiver from the Hong Kong Stock Exchange.
• Major Customers and Suppliers:
  • No single customer or supplier accounted for more than 30% of revenue or purchases, indicating a diversified operational base.
• Environmental, Social, and Governance:
  • The company claims compliance with all relevant PRC and Hong Kong regulations and has published a standalone ESG report.

Risks and Considerations for Investors

• Price-Sensitive and Potentially Market-Moving Information:
  • The disclaimer of opinion from the auditors regarding the going concern status is highly price sensitive and could significantly impact market confidence and share valuation.
  • The substantial net loss and large volume of short-term borrowings due in 2026, with repayment issues already evident, increases the risk of default or restructuring.
  • The Group’s plan to sell assets and restructure liabilities, while necessary, introduces execution risk and may not be completed in time or at favorable prices.
  • Any failure to secure new financing, renegotiate debt maturities, or sell assets could result in material asset write-downs, further losses, or even insolvency.
  • No dividend payout for 2025, further highlighting the Group’s constrained cash flow.
• Potential Share Price Catalysts:
  • Any successful debt restructuring, significant asset sales, or improvement in property sales could alleviate liquidity pressures and be viewed positively by the market.
  • Conversely, announcement of defaults, further losses, or failure of the Group’s plans could drive the share price lower.

Additional Company Information

• AGM Date: June 30, 2026 (Register closure from June 24-30, 2026).
• Auditors’ Remuneration: RMB 2 million for audit services in 2025.
• Charitable Donations: Nil in 2025 (RMB 0.06 million in 2024).
• Directors Standing for Re-election: Mr. Zhang Zhangsun, Mr. Yang Huabin, Mr. Deng Zhidong, and Mr. Wang Shiyu (appointed Dec 1, 2025).

Conclusion

The 2025 Annual Report for Glory Health Industry Limited reveals a company facing severe financial distress, with a sizeable net loss, heavy short-term debt maturities, and auditor doubts about its ability to continue as a going concern. These are highly material and price-sensitive issues. While management is taking steps to address the situation through asset sales and debt negotiations, substantial uncertainty remains. Investors should exercise extreme caution until there is clarity on the success of these measures.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should consult their own advisors and review the full annual report and disclosures before making any investment decisions. The company’s financial position is subject to significant uncertainties, and there is a risk of further adverse developments.

View GLORY HEALTH Historical chart here